Research programme: epithelial sodium channel inhibitors - Parion SciencesAlternative Names: P-1055
Latest Information Update: 08 Jul 2015
At a glance
- Originator Parion Sciences
- Mechanism of Action Epithelial sodium channel-antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Bronchiectasis; Chronic obstructive pulmonary disease; Cystic fibrosis